Dynocardia has now received nearly $5.1 million in funding from the NHLBI to help speed commercializing its wrist-worn monitor to avoid the need for invasive catheter BP monitoring.

The new report could go on to help guide decisions made by CMS and hospital leadership teams for years to come.

Cardiologists and other physicians may soon need to provide much more information when ordering remote patient monitoring for Medicare patients.

Two medical device companies have announced a transaction that could shake up the U.S. electrophysiology market. 

Medtronic and Abbott are often seen as rivals in a competitive marketplace, but the two companies are collaborating with a simple goal in mind: improving patient access to high-quality CGM devices. 

As profit margins in healthcare continue to shrink, telemedicine and remote monitoring are seeing a large increase to help cut costs while still delivering care outside of the hospital.

The new algorithm from Implicity evaluates implantable device data and monitors patients for changes that suggest they could experience severe heart failure symptoms in the near future. It was designed to alert clinicians up to weeks in advance.

Only radiology is associated with more FDA-cleared AI algorithms than cardiology, according to new federal data.